NanoVibronix (NAOV) issues shareholder letter via 8-K filing

NanoVibronix, Inc. (NAOV) filed a current report announcing that it issued a shareholder letter on November 19, 2025.

Rhea-AI Filing Summary

NanoVibronix, Inc. (NAOV) filed a current report announcing that it issued a shareholder letter on November 19, 2025. The letter was provided to investors as an exhibit to this report under a disclosure rule that covers company communications with the market, rather than as a formal financial or earnings filing. The report clarifies that this communication is being furnished, not filed, which means it is not automatically incorporated into other securities law filings or subject to certain legal liabilities.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NanoVibronix (NAOV) announce in this 8-K filing?

NanoVibronix announced that it issued a shareholder letter dated November 19, 2025, which is attached as Exhibit 99.1 to the report.

Is the NanoVibronix shareholder letter considered filed with the SEC?

No. The company states the shareholder letter is being furnished under a disclosure item and is not deemed filed for purposes of Section 18 of the Exchange Act.

Does this NanoVibronix 8-K include financial results or earnings data?

No specific financial results or earnings data are described in this report. It mainly notes the existence of the shareholder letter as an exhibit.

Which exhibit in the 8-K contains the NanoVibronix shareholder letter?

The shareholder letter is included as Exhibit 99.1, titled "Shareholder Letter, dated November 19, 2025."

Who signed the NanoVibronix 8-K report?

The report was signed on behalf of NanoVibronix, Inc. by Doron Besser, M.D., the company’s Chief Executive Officer.

What stock exchange is NanoVibronix (NAOV) listed on?

NanoVibronix’s common stock, trading under the symbol NAOV, is listed on the Nasdaq Capital Market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/19/2025 - 08:00 AM EST Learn about SEC filing dates

false 0001326706 0001326706 2025-11-19 2025-11-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 19, 2025

NanoVibronix, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-36445		01-0801232
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

969 Pruitt Ave Tyler, Texas		77569
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (914) 233-3004

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, par value $0.001 per share		NAOV		Nasdaq Capital Market

Item 7.01 Regulation FD.

On November 19, 2025, NanoVibronix, Inc. issued a letter to its stockholders (the “Shareholder Letter”). A copy of the Shareholder Letter is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K (including the exhibit attached as Exhibit 99.1 hereto) is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act (including the exhibit attached as Exhibit 99.1 hereto).

Exhibit Number		Description of Exhibit
99.1		Shareholder Letter, dated November 19, 2025 (furnished herewith under Item 7.01).
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NanoVibronix, Inc.
Date: November 19, 2025	By:	/s/ Doron Besser, M.D.
	Name:	Doron Besser, M.D.
	Title:	Chief Executive Officer